Transformative Diagnostic Solutions in Cancer and Other Diseases

With a rich history of scientific firsts in genomic testing for cancer, we provide high-quality precision diagnostic solutions at each stage of the patient experience and help accelerate the development of new personalized therapies to improve lives today and for generations to come.

Access Content Tailored to You

Healthcare Providers Biopharma Partners Patients and Caregivers

Setting the Standard for High-Quality Genomic Testing

Supported

950+

clinical trials¹

More than

2,400

research publications,

two times more than 
any other comprehensive genomic profiling (CGP) company²

Over

1.5 million

patient CGP reports delivered³

Historic milestone of

100

approved companion diagnostic indications

for next-generation sequencing⁴˒⁵

We forged the path for high-quality genomic testing in cancer as one of the first companies to recognize the promise of precision medicine and use a patient’s unique genomic makeup to help healthcare providers develop a personalized treatment approach. Today, we are building on that foundation, expanding our diagnostic capabilities to transform care in cancer and other diseases throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. By investing in new technologies and digital platforms, including powerful AI-enabled tools, we can accelerate scientific discovery, expanding the information our diagnostic solutions provide and enabling improved outcomes for patients living with cancer and other diseases.

Explore All Solutions

Explore by Role

Find the information, tools and support most relevant to you.

For Patients and Caregivers

Find clear, reliable information to help you understand more about biomarker testing, your test results and what it may mean for your treatment journey.

Visit the Patient Hub

For Healthcare Providers

Access trusted genomic profiling, clinical interpretation and tools that support confident decisions at every stage of care.

Visit the Provider Hub

For Biopharma Partners

Partner with a global leader in genomic data and diagnostics to accelerate discovery, de-risk development and support therapy launch.

Visit the Biopharma Hub
hands holding cdx test and writing

Browse by Solution

See Foundation Medicine's complete portfolio, including our U.S. Food and Drug Administration-approved tissue- and blood-based CGP tests.

Information for healthcare providers and biopharma partners.

Explore All Solutions

Hear from Patients

Hear from patients and advocates on their experience with Foundation Medicine testing.

Strengthen in Answers with Biomarker Testing

Summer

Now Playing

A Personalized Approach to Colon Cancer

Trevor

Watch Video

Advocacy for Biomarker Testing in Prostate Cancer

Lonnie

Watch Video

Latest Events and Insights

Explore All Resources
Press Release
Foundation Medicine Drives Awareness on the Importance of Quality and Accuracy in Cancer Biomarker Testing
Foundation Medicine launches Quality First, an initative to drive awareness about the importance of high-quality biomarker testing in cancer care.
Read More
Press Release
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to
Read More
Press Release
US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx a
Read More

References

  1. Data on File, Foundation Medicine, Inc., 2024
  2. Data on File, Foundation Medicine, Inc., 2025
  3. Data on File, Foundation Medicine, Inc., 2025
  4. U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Updated December 17, 2025. Accessed January 16, 2026. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
  5. Pharmaceuticals and Medical Devices Agency. List of approved CDx in Japan. Updated December 16, 2025. Accessed January 16, 2026. https://www.pmda.go.jp/english/rs-sb-std/rs/0027.html